DA
Therapeutic Areas
Monte Rosa Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MRT-2359 | MYC-driven solid tumors and lymphomas | Phase 1/2 |
| MRT-6160 | Inflammatory and autoimmune diseases | Preclinical |
| CDK2 Degrader | Oncology | Preclinical |
Leadership Team at Monte Rosa Therapeutics
DM
Dr. Markus Warmuth, M.D.
President, Chief Executive Officer, and Director
DS
Dr. Sharon Townson, Ph.D.
Chief Scientific Officer
PV
Philip Vickers, Ph.D.
Head of Research & Development
CR
Christopher R. L. Cline, CFA
Chief Financial Officer
DJ
Dr. John Tsai, M.D.
Chair of the Board of Directors
DT
Dr. Thomas G. Wiggans
Director
DT
Dr. Thomas J. Kelly, M.D., Ph.D.
Director
DT
Dr. Thomas C. Reynolds, M.D., Ph.D.
Director
DT
Dr. Thomas B. Neff
Director
DB
Dr. Brenda Schulman
Scientific Advisory Board Member